GlassScriptPhysician profile
Timothy Lee Schoonover
NPI 1033111802
$386,769.83
in general payments reported to CMS, 2019-2025
70 companies · $40K in 2025
The $40K reported for 2025 was more than what 95% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $102K · 2020: $45K · 2021: $92K · 2022: $61K · 2023: $27K · 2024: $21K · 2025: $40K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $72K · Food and Beverage: $11K · Travel and Lodging: $4,170 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,025.00 |
| Food and Beverage | $11,007.37 |
| Travel and Lodging | $4,169.74 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $151,469.73 | 2019-2025 | Botox, Qulipta, Ubrelvy |
| Amgen INC. | $104,757.30 | 2019-2023 | Aimovig |
| Allergan, INC. | $80,446.60 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $35,164.88 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $1,437.60 | 2019-2025 | |
| Ucb, INC. | $1,016.00 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Emd Serono, INC. | $867.17 | 2019-2025 | Mavenclad |
| Alexion Pharmaceuticals, INC. | $787.02 | 2020-2025 | Ultomiris, Soliris |
| Lilly USA, LLC | $661.48 | 2019-2025 | Amyvid, Emgality, Reyvow |
| Pfizer INC. | $646.06 | 2022-2025 | |
| Biogen, INC. | $639.50 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Neurocrine Biosciences, INC. | $543.51 | 2021-2025 | Ingrezza, Ongentys |
| Eisai INC. | $511.30 | 2020-2025 | |
| Supernus Pharmaceuticals, INC. | $488.30 | 2019-2022 | |
| Genzyme Corporation | $466.65 | 2019-2025 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mdd US Operations, LLC | $451.80 | 2019-2025 | Gocovri, Gocovri |
| Sk Life Science, INC. | $449.09 | 2020-2025 | |
| Amneal Pharmaceuticals LLC | $419.02 | 2019-2025 | Crexont, Rytary, Lyvispah |
| Acadia Pharmaceuticals INC | $393.18 | 2019-2025 | Nuplazid |
| Genentech USA, INC. | $364.01 | 2019-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Biohaven Pharmaceutical Holding Company LTD. | $351.12 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $312.46 | 2020-2021 | |
| Lundbeck LLC | $312.27 | 2019-2025 | Vyepti |
| Acorda Therapeutics, INC | $273.26 | 2019-2024 | Inbrija |
| Janssen Pharmaceuticals, INC | $260.62 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $234.69 | 2019-2025 | |
| Insightec,INC | $231.11 | 2023-2025 | Exablate |
| Argenx US, INC. | $227.94 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Sunovion Pharmaceuticals INC. | $167.25 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $162.81 | 2023-2025 | Hyqvia, Gammagard |
| Hyperfine Operations, INC. | $155.60 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $132.28 | 2022-2025 | Dysport |
| Alnylam Pharmaceuticals INC. | $132.04 | 2020-2022 | |
| Abbott Laboratories | $128.59 | 2022 | |
| Merz Pharmaceuticals, LLC | $119.98 | 2022-2025 | Xeomin, Ampyra, Inbrija |
| Greenwich Biosciences, INC. | $117.84 | 2019-2021 | |
| Kyowa Kirin, INC. | $106.28 | 2020-2024 | Nourianz |
| Neurelis, INC. | $101.71 | 2021-2025 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $99.55 | 2021-2025 | Wainua |
| Adamas Pharmaceuticals, INC. | $97.67 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $96.37 | 2019-2022 | |
| Ge Healthcare | $95.25 | 2022-2024 | |
| Tg Therapeutics, INC. | $77.67 | 2023 | |
| Csl Behring | $68.93 | 2020-2023 | Privigen |
| Grifols USA, LLC | $68.54 | 2019-2024 | Gamunex-C |
| Sumitomo Pharma America, INC. | $65.86 | 2023 | Aptiom |
| Harmony Biosciences LLC | $62.26 | 2020-2025 | |
| Octapharma USA, INC. | $58.84 | 2022-2023 | Panzyga |
| Revance Therapeutics, INC. | $48.35 | 2024-2025 | Daxxify |
| Portola Pharmaceuticals, LLC | $36.67 | 2019 | |
| Amylyx Pharmaceuticals, INC. | $36.08 | 2023 | Relyvrio |
| Axsome Therapeutics, INC. | $32.96 | 2023-2024 | Sunosi |
| Currax Pharmaceuticals LLC | $32.49 | 2022-2023 | Onzetra Xsail |
| Merz North America, INC. | $31.92 | 2019 | |
| Tanabe Pharma America, INC. | $31.84 | 2019-2023 | |
| Boston Scientific Corporation | $26.27 | 2022 | |
| Sandoz INC. | $25.53 | 2024 | |
| Averitas Pharma INC. | $24.72 | 2023 | Qutenza |
| Horizon Therapeutics Plc | $22.66 | 2022 | |
| Philips North America LLC | $22.19 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $20.68 | 2023 | Nuedexta |
| Aprecia Pharmaceuticals, LLC | $20.66 | 2023 | Spritam |
| Cala Health, INC. | $17.14 | 2022 | |
| Springworks Therapeutics, INC. | $15.04 | 2025 | Gomekli |
| Corium, LLC | $13.13 | 2023 | Adlarity |
| Alfasigma USA, INC. | $12.51 | 2020 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5,252.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
$138,168.76 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Schoonover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.